Craft

Inovio Pharmaceuticals

Stock Price

$5.6

2024-10-29

Market Capitalization

$144.4 M

2024-10-29

Revenue

$65.3 K

FY, 2025

Inovio Pharmaceuticals Summary

Company Summary

Overview
Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Type
Public
Status
Active
Founded
1979
HQ
Plymouth Meeting, PA, US | view all locations
Website
http://www.inovio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Angel Cabrera, Director

    • Peter Kies

      Peter Kies, Chief Financial Officer

    • Laurent Humeau

      Laurent Humeau, Chief Scientific Officer

      • J. Joseph Kim

        J. Joseph Kim, President, CEO, Director

      Operating MetricsView all

      Patents Issued

      620

      FY, 2016

      LocationsView all

      3 locations detected

      • Plymouth Meeting, PA HQ

        United States

        660 W Germantown Pike #110

      • San Diego, CA

        United States

        10480 Wateridge Cir

      • San Diego, CA

        United States

        6769 Mesa Ridge Rd

      Inovio Pharmaceuticals Financials

      Summary Financials

      Cash (Q1, 2026)
      $26.3M
      EBIT (Q1, 2026)
      ($21.9M)
      Enterprise value
      $106.6M

      Footer menu